| Quarter | Score |
|---|---|
| 2022-Q3 | 41.1 |
| 2022-Q4 | 49.2 |
| 2023-Q1 | 49.0 |
| 2023-Q2 | 66.8 |
| 2023-Q3 | 48.0 |
| 2023-Q4 | 65.9 |
| 2024-Q1 | 63.4 |
| 2024-Q2 | 73.6 |
| 2024-Q3 | 57.7 |
| 2024-Q4 | 57.8 |
| 2025-Q1 | 35.4 |
| 2025-Q2 | 62.6 |
| 2025-Q3 | 62.4 |
| 2025-Q4 | 87.9 |
| 2026-Q1 | 86.1 |
| 2026-Q2 | 86.3 |
High consensus with active accumulation at an attractive valuation
Trading 84.1% below funds' estimated purchase price
2 of 18 tracked funds hold CVNA. Avg conviction: 3.1%. Net adding. First tracked at $379.49 (current -84.1% vs tracked).
Sachem Head Capital has 6.1% in this stock
Benchmark comparison unavailable
Prices are approximate, based on 13F reported values (position value / shares), not actual cost basis. Data covers 17 tracked value-oriented funds. Holdings are reported quarterly with a ~45-day lag. Stock splits may affect share count comparisons. Returns are not annualized.
| Fund | % of Portfolio | Action |
|---|---|---|
| Sachem Head Capital | 6.1% | Add |
| Citadel Advisors | 0.0% | Add |